Preclinical studies using transgenic mice expressing human CD19 have shown that pre-B cells and their malignant counterparts, as well as pre-existing antibody-producing and autoantibody-producing ...
At the end of the incubation the cells were spun, supernatant aspirated, and the cells were stained with rat anti-mouse CD11b (Pacific blue), CD5 (PE), CD19 (APC), and incubated for 30 min on ice. The ...
Targeted therapy approaches are increasingly implemented in cancer therapy regimens, often complementing conventional treatments (e.g., chemotherapy, radiation). Among these novel strategies, targeted ...
4.2 Current status of CD19-CAR-T cell therapy for systemic sclerosis and autoimmune disease Existing research has preliminarily confirmed the feasibility and potential benefits of CD19 CAR-T cell ...
The cell nuclei were stained with hematoxylin for 3 min at 25°C. For immunofluorescence, after being incubated with primary antibodies (anti-cleaved-Caspase-3, anti-phospho-MLKL (S345), anti-F4/80, ...
This case of a successful treatment of multi-refractory primary immune thrombocytopenia adds to the growing body of evidence supporting the use of CD19 CAR T-cell therapy in B cell-driven autoimmune ...
Bacterial outer membrane vesicles (OMVs) have emerged as promising vehicles for anticancer drug delivery due to their inherent tumor tropism, immune-stimulatory properties, and potential for ...